MRK - Merck & Co., Inc.
| Previous close | 85.36 |
| Open | 85.98 |
| Bid | 84.49 x 800 |
| Ask | 84.51 x 1800 |
| Day's range | 84.33 - 86.50 |
| 52-week range | 59.80 - 86.50 |
| Volume | 5,194,843 |
| Avg. volume | 10,195,300 |
| Market cap | 217.287B |
| Beta (3Y monthly) | 0.29 |
| PE ratio (TTM) | 26.65 |
| EPS (TTM) | 3.17 |
| Earnings date | 30 Jul 2019 |
| Forward dividend & yield | 2.20 (2.58%) |
| Ex-dividend date | 2019-06-14 |
| 1y target est | 88.93 |
- Simply Wall St.•18 minutes ago
Should You Be Adding Merck (NYSE:MRK) To Your Watchlist Today?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
- Zacks•3 hours ago
Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice
Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•3 hours ago
Stock Market News For Jun 20, 2019
Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
- Zacks•4 hours ago
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
- Business Wire•6 hours ago
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Merck is very well positioned to pursue its mission to save and improve lives,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
- Zacks•yesterday
Merck's Keytruda Gets 2nd Label Expansion Approval in June
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
- Business Wire•yesterday
AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA is the Only PARP Inhibitor Approved in Japan
- Zacks•2 days ago
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.
- Zacks•2 days ago
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
- Zacks•2 days ago
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
- MarketWatch•2 days ago
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
- Business Wire•2 days ago
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC
- Business Wire•2 days ago
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Tri
- Reuters - UK Focus•2 days ago
UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.
- Zacks•3 days ago
Bayer to Invest 5 Billion Euros in Weedkiller Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
- Zacks•3 days ago
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
- Market Realist•3 days ago
Merck’s Inorganic Growth Strategy in 2019
On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.
- Zacks•3 days ago
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
- Market Realist•3 days ago
How Are Merck’s Revenues Trending in 2019?
On its first-quarter earnings conference call, Merck & Co. (MRK) guided for 2019 revenue of $43.9 billion–$45.1 billion, a YoY (year-over-year) rise of 4%–7% driven by its Oncology, Hospital and Specialty, Vaccines, and Animal Health segments.
- Market Realist•3 days ago
What Analysts Recommend for Merck and AstraZeneca in June
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
- Simply Wall St.•3 days ago
How Many Merck & Co., Inc. (NYSE:MRK) Shares Have Insiders Sold, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- Zacks•6 days ago
Agilent Announces Receipt of FDA Approval for pharmDX Assay
Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
- Zacks•6 days ago
3 Big Pharma Stocks to Buy Right Now
These big pharma stocks all have a Zacks Rank 2 or better.
- Barrons.com•6 days ago
Merck Plans Its First Investor Day in 5 Years. Here’s What to Watch.
Analysts say that the event will be vital for the pharmaceutical company as it seeks to show investors it can build on a strong run in recent years.
- Zacks•6 days ago
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
The index traversed a volatile week, guided largely by trade-related developments.
